NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides ... mechanisms of action and strong safety profiles, MediciNova has ...
The TOPSPIN Study demonstrates that once a day single pill combination of two blood pressure lowering drugs can control blood ...
The trial is structured as a non-randomised ... showing signs of drug activity while not reporting any safety issues. One ...
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma ...
CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...
In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...
The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback